铁激素结合抑制剂免疫球蛋白对心房的长期影响在甲状腺患者中
Jung-Chi Hsu1, Kang-Chih Fan2, Ting-Chuan Wang3
1Division of Cardiology, Department of Internal Medicine, National Taiwan University Hopistal Jinshan Branch, New Taipei City, Taiwan; Division of Cardiology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
概括
甲状腺炎治疗后甲状腺炎患者甲状腺蛋白结合抑制免疫球蛋白 (TBII) 水平升高与心房动 (AF) 和心血管死亡风险增加有关. 将TBII降低到35%以下可能会改善临床结果.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 甲状腺功能障碍症增加了心房动 (AF) 的风险.
- 在甲状腺正常化后,自抗体在AF和心血管死亡率中的作用尚不清楚.
研究的目的:
- 调查甲状腺腺素结合抑制免疫球蛋白 (TBII) 水平与非甲状腺体和心血管死亡的长期风险之间的关联.
主要方法:
- 利用了14618名患者 (2000-2022) 的电子病历.
- 使用多变量考克斯回归和卡普兰-梅尔分析评估了TBII水平和AF/心血管死亡率之间的关系.
主要成果:
- 升高的TBII (>35%) 与显著增加的AF风险相关 (HR 1.48-1.91).
- 较高的TBII水平与心血管死亡率相关 (HR 6.73-7.87).
- 卡普兰-梅尔分析证实TBII升高增加了AF和心脏死亡风险 (日志排名P <.05).
结论:
- 升高的TBII水平和负担与长期AF和心血管死亡风险有关,在安甲状腺患者治疗后的抗甲状腺治疗.
- 将TBII水平降低到35%以下可能有利于临床结果.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
988
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
988
Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Synthesis and Regulation of Thyroid Hormones
4.6K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.6K
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337


